Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Neurologix holds license for gene therapy to treat severe depression

Neurologix, Inc. today announced that a landmark paper, published on October 20th in Science Translational Medicine demonstrating the importance of the p11 gene in modulating depression in mice, utilized a gene therapy approach to reverse depression in mice for which the Company holds exclusive development rights. Based on the findings reported in the paper, gene therapy may have potential as a new treatment option for people who suffer from severe depression.

26 Oct 2010

Study on gene variant associated with narcolepsy

Ever wonder why some people breeze along on four hours of sleep when others can barely function? It may be in our genes, according to new research and an accompanying editorial published in the October 26, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

26 Oct 2010

UCI scientists receive CIRM grants to improve stem cell treatments

UC Irvine scientists will receive grants totaling $9.35 million to help create stem cell treatments for retinitis pigmentosa, Huntington's disease and traumatic brain injury.

25 Oct 2010

$Cedars-Sinai to develop world's first biological treatment for compression fractures$

Cedars-Sinai to develop world's first biological treatment for compression fractures

A team of physicians and scientists from the Cedars-Sinai Regenerative Medicine Institute and Department of Surgery, led by Dan Gazit, DMD, PhD has been awarded a three-year $1.9 million grant from the California stem cell agency to fund research leading to clinical trials for what could become the first biological treatment for the most common type of bone fracture in osteoporosis patients.

25 Oct 2010

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled "Biomarkers of Metabolic Responses to Hepatic Drugs". The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.

21 Oct 2010

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

20 Oct 2010

Vitamin B12 may help protect against Alzheimer's disease

A new study shows that vitamin B12 may protect against Alzheimer's disease, adding more evidence to the scientific debate about whether the vitamin is effective in reducing the risk of memory loss. The research will be published in the October 19, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

19 Oct 2010

UCSF professor receives National Medal of Science

UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.

18 Oct 2010

Galenea awarded $4.5M NIMH grant to advance Multiwell, Automated NeuroTRansmission Assay platform

Galenea Corp. has been awarded a highly competitive grant from the National Institute of Mental Health in response to the solicitation "Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)," funded by the American Recovery and Reinvestment Act of 2009. Galenea has developed an innovative technology platform, termed MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) that enables high-throughput screening for the identification of small molecule modulators of synaptic transmission.

14 Oct 2010

Walking six miles per week preserves memory in old age

New research suggests that walking at least six miles per week may protect brain size and in turn, preserve memory in old age, according to a study published in the October 13, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

14 Oct 2010

Women with epilepsy at risk of infertility

Women with epilepsy may be more likely to experience infertility, according to new research published in the October 12, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

12 Oct 2010

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.

7 Oct 2010

Researchers investigate ways to increase survival rate in patients with Parkinson's disease

New research shows how old people are when they first develop Parkinson's disease is one of many clues in how long they'll survive with the disease. The research is published in the October 5, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).

30 Sep 2010

CAP meeting to highlight medical diagnostic procedures

New science in cancer, genetic testing, molecular diagnostics, medical ethics, and gender-based disorders will be featured topics when nearly 1,200 pathologists gather at the Hyatt Regency Chicago on September 26 - 29 for the annual scientific meeting of the College of American Pathologists (CAP).

24 Sep 2010

New study signals hope for treatment of rare neurodegenerative disease

A new study led by St. Jude Children's Research Hospital scientists signals hope for treatment of a neurodegenerative disease and a new model for understanding the mechanism at work in other more common neurodegenerative disorders.

23 Sep 2010

Study on spinal cord stem cells paves way for post stroke symptom treatment

Neuralstem, Inc. announced that its spinal cord stem cells survived in rat brains affected by stroke and differentiated predominantly into neurons. The transplanted animals showed significant improvement in some motor skill and strength measurements. The study entitled, "Intracerebral Implantation of Adherent Human Neural Stem Cells To Reverse Motor Deficits in Chronic Stroke Rats," was presented earlier today by senior study author, Dr. Shinn-Zong Lin, M.D., Ph.D., at the Stem Cells USA & Regenerative Medicine Conference

15 Sep 2010

Metabolon receives patent for metabolic age analysis

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,781,160 entitled "Biomarkers Related to Metabolic Age and Methods Using the Same". The USPTO awarded the patent to Metabolon on August 24, 2010. This is the 12th patent issued to Metabolon.

14 Sep 2010